Brookline Capital Markets Fortifies Ranks for Healthcare & SPAC Push

NEW YORK, NY – January 22, 2026 – In a clear signal of its ambitious growth strategy, boutique investment bank Brookline Capital Markets has announced the significant expansion of its team with four senior-level appointments. The move strengthens the firm's core capabilities across banking, equity sales, research, and corporate access, reinforcing its specialized focus on the dynamic healthcare, Special Purpose Acquisition Company (SPAC), and emerging growth sectors.

The new hires—Neha Motwani, Brian McKenna, Fozia Ahmed, Ph.D., and Connor Norton—bring a wealth of experience from prominent Wall Street firms, underscoring Brookline's ability to attract top-tier talent in a fiercely competitive market. The announcement comes as the firm continues to navigate and capitalize on complex market conditions within its niche verticals.

"Our growth continues unabated," stated William B. Buchanan, Jr., Managing Partner at Brookline Capital Markets, in the official announcement. "These four hires represent the next step forward for Brookline in Banking, Equity Sales, Equity Research, and Corporate Access. We remain fiercely committed to our role as a premier investment banking boutique on Wall Street."

Bolstering the Ranks with Veteran Expertise

The caliber of the new additions speaks volumes about Brookline's strategic intent. Each professional brings a deep and specialized skill set that directly aligns with the firm's operational pillars.

Joining as a Managing Director in banking, Neha Motwani brings over 25 years of dedicated biopharma investment banking experience. Her impressive resume includes senior roles at William Blair, Truist Securities, Oppenheimer, and Cowen. Having advised on transactions valued at over $7 billion, including complex M&A and a wide array of equity financings, her arrival significantly deepens Brookline's deal-making prowess in the life sciences arena. Her extensive network and track record are expected to be instrumental in sourcing and executing high-value transactions for the firm's growing client base.

Brian McKenna joins as a Managing Director specializing in institutional research sales. His career path includes leadership positions at Roth Capital Partners, Cantor Fitzgerald, and William Blair. McKenna's expertise lies in connecting proprietary research with the institutional investors who drive market activity. His role will be crucial in amplifying the reach and impact of Brookline's equity research platform, enhancing liquidity for its corporate clients and strengthening the firm's relationships with major funds.

Brookline's highly specialized equity research department gains further scientific credibility with the addition of Fozia Ahmed, Ph.D., as an Associate Analyst. Dr. Ahmed holds a Ph.D. in Materials Science & Engineering and a Master’s in Biotechnology from Johns Hopkins University. Her background, which includes prior equity research roles at firms like Roth Capital Partners and EF Hutton, combines rigorous scientific acumen with financial analysis—a critical combination for evaluating cutting-edge biotech and medical technology companies. Her expertise in areas like receptor tyrosine kinases and therapeutic agents for brain cancers provides the kind of granular insight that sophisticated healthcare investors demand.

Rounding out the strategic hires is Connor Norton, who will serve as the new Head of Corporate Access. With a background in neuroscience and experience at Third Bridge Group and Global Investment Advisory, Norton has a proven ability to bridge the gap between corporate management teams and the hedge fund community. His expertise in primary market research and capital allocation analysis will enhance Brookline’s ability to facilitate meaningful, high-impact interactions between its clients and the investment world.

A Calculated Move in a Shifting Market

Brookline's talent acquisition is not happening in a vacuum. It represents a calculated response to the evolving landscape of healthcare and SPAC financing. While the broader markets have faced volatility, the healthcare sector has demonstrated resilience and continued demand for capital. Brookline's own market analysis from 2025 noted a significant year-over-year increase in follow-on offering proceeds in 2024, indicating a robust appetite for funding within the life sciences and med-tech industries. By adding Motwani's biopharma banking expertise and Ahmed's deep scientific research capabilities, the firm is positioning itself to capture a larger share of this active market.

Simultaneously, the SPAC market, though having cooled from its frenetic peak, remains a viable and important tool for private companies seeking to go public. Brookline has maintained a steady presence in this space, advising on multiple SPAC mergers and financings throughout 2024 and 2025. The firm's continued investment in its SPAC practice suggests a long-term belief in the vehicle's utility, particularly for the types of emerging growth companies it specializes in. These hires collectively enhance the full-service advisory model—from initial research to deal execution and post-deal investor relations—that is essential for successfully navigating the intricacies of SPAC transactions.

The Boutique Advantage in Wall Street's Talent War

The ability of a boutique firm like Brookline to attract seasoned managing directors from larger, more diversified institutions highlights a key trend on Wall Street: the appeal of specialization. In an industry often dominated by bulge-bracket behemoths, specialized boutiques offer an environment where deep industry expertise is paramount. For professionals like Motwani and McKenna, the move to a firm like Brookline can provide greater agility, a more focused mandate, and the opportunity to have a more direct impact on the firm's trajectory.

This talent grab validates the firm's claim of "unabated growth." A review of its recent transaction history shows a consistent flow of deals, including roles as co-manager on IPOs, financial advisor on nine-figure acquisitions, and bookrunner on various offerings. This sustained activity creates a compelling narrative for prospective hires, demonstrating a platform where their skills can be immediately and effectively deployed. By investing in top-tier talent, Brookline is not just filling seats; it is making a strategic play to outmaneuver competitors by offering a level of specialized knowledge and senior-level attention that larger firms may struggle to consistently provide.

This expansion is a testament to the firm’s ambition to solidify its standing as a go-to advisor in its chosen fields. By integrating these new professionals, Brookline is not only enhancing its current service offerings but is also building the foundation needed to seize future opportunities and guide its clients through the next wave of innovation and capital formation in the healthcare and emerging growth economies.